Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vito Sabato

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
The Journal of Investigative Dermatology|February 13, 2021
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on MastocytosisElisabeth Aberer, Wolfgang R Sperr, Agnes Bretterklieber, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 3, 2023
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future PerspectivesPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2020
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the SkinDavid Fuchs, Alex Kilbertus, Karin Kofler, et al.
Pediatric Rheumatology Online Journal|October 17, 2022
Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases - a proof of concept studyMy Kieu Ha, Esther Bartholomeus, Luc Van Os, et al.
Allergy|February 29, 2020
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classificationJakub Trizuljak, Wolfgang R Sperr, Lucie Nekvindová, et al.
Leukemia|January 15, 2025
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on MastocytosisAxel Rüfer, Henning Nilius, Olivier Hermine, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
The Journal of Investigative Dermatology|February 13, 2021
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on MastocytosisElisabeth Aberer, Wolfgang R Sperr, Agnes Bretterklieber, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 3, 2023
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future PerspectivesPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2020
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the SkinDavid Fuchs, Alex Kilbertus, Karin Kofler, et al.
Pediatric Rheumatology Online Journal|October 17, 2022
Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases - a proof of concept studyMy Kieu Ha, Esther Bartholomeus, Luc Van Os, et al.
Allergy|February 29, 2020
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classificationJakub Trizuljak, Wolfgang R Sperr, Lucie Nekvindová, et al.
Leukemia|January 15, 2025
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on MastocytosisAxel Rüfer, Henning Nilius, Olivier Hermine, et al.
Pageof 21